Evaluation of Humira Retention Rate in Psoriasis Patients in Daily Practice and Assessment of Work Productivity and Quality of Life

Study Identifier
P12-129
CT.gov Identifier
NCT01169987
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Results Available

Scientific Result Summary
Available Language(s): English
Download document(s)

Study Details

Medical Condition
  • Dermatology - Psoriasis (PsO)
    • Study Drug
    N/A
    Phase
    N/A
    Sex
    Female & Male
    Age
    18 - 99 Years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * Patients \> or = 18 years * Patient with chronic plaque psoriasis * Patient newly initiated on Humira * Patient compliant with Humira Summary of Product Characteristics * Patient compliant with Belgian reimbursement criteria of Humira in plaque psoriasis * Patient has signed informed consent
    Exclusion Criteria:
    * Patients having any of the contraindications mentioned in the Summary of Product Characteristics Humira * Patients not willing to sign informed consent

    Protocol Summary

    This observational study will document to what extent in daily clinical practice Humira (adalimumab) therapy is continued, interrupted or permanently discontinued during a follow-up period of 2 years. Reasons for interrupting or permanently discontinuing Humira therapy and reasons for restarting Humira therapy will be noted. An evaluation will be performed of the effect of the disease on quality of life and work productivity.

    Study Locations

    No locations found.